Optimice-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Disease Sites:

Breast

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics, Supportive Care

Drugs:

Not Available

Principal Investigator(s):

Abramson, Vandana

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

05-28-2024

Trial Type:

Treatment

Protocol ID:

VICC-NTBRE23357

National Clinical Trial ID:

NCT05812807

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available